Former Chief Financial Officer · Inhibikase Therapeutics, Inc. (IKT)

Joseph Frattaroli

A named executive officer of Inhibikase Therapeutics in every fiscal year CompBrief holds from FY2019 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$579,964

Salary $408,333Stock awards $0

FY2022: $574,765

2nd of 2 named executive officers at Inhibikase Therapeutics by FY2023 total.

2 named officers on file for Inhibikase Therapeutics, FY2023

Joseph Frattaroli’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Inhibikase Therapeutics’s whole pay program stands against its peers

  • Inhibikase Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IKT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Joseph Frattaroli’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Joseph Frattaroli compensation by year

Inhibikase Therapeutics Summary Compensation Table · all 5 fiscal years held
In US dollars, as Inhibikase Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023
Salary$300,000$300,000$375,000$395,833$408,333
Bonus$0$0$0$0$0
Stock awards$0$0$0$0$0
Option awards$0$1,342,220$0$42,932$48,631
Non-equity incentive$0$0$0$136,000$123,000
Pension and deferred compensation$0$0$0$0$0
All other$0$0$0$0$0
Total$300,000$1,642,220$375,000$574,765$579,964

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Inhibikase Therapeutics, Inc. DEF 14A filed April 26, 2024, accession 0000950170-24-049145, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Inhibikase Therapeutics, Inc. filed document, accession 0000950170-24-049145. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$300K
$1.6M
$375K
$575K
$580K
FY19
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveOption awards

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option4,304—$6.42
Option7,500—$4.44
Option15,000—$4.44
Option20,834—$6.42

Per the Outstanding Equity Awards at Fiscal Year-End table in Inhibikase Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Inhibikase Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Milton WernerPresident and Chief Executive Officer$811,429
Joseph Frattaroli · this pageFormer Chief Financial Officer$579,964

Board service

Inhibikase Therapeutics board · FY2023

How this board is paid

Company policy: Inhibikase Therapeutics pays directors a $40,000 cash retainer and $16,854 in Options. As stated in Inhibikase Therapeutics's FY2023 proxy.

The full Inhibikase Therapeutics compensation record

free company brief

This page is one person within Inhibikase Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Inhibikase Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Joseph Frattaroli's compensation dossier · One-time report. No refunds.